CSCI COSCIENS BIOPHARMA INC

COSCIENS Comments on Unusual Market Activity

COSCIENS Comments on Unusual Market Activity

TORONTO, ONTARIO, April 07, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is issuing this news release in response to unusual market activity. While the Company does not normally comment on market activity or market speculation, the Company confirms that it is not aware of any material undisclosed information relating to the Company that would account for the recent increase in trading activity in, and trading price of, the Company’s common shares.

About COSCIENS Biopharma Inc.



COSCIENS is a life science company focused on the development of natural, plant-based active ingredients, leveraging the Company’s proprietary manufacturing and extraction technologies to develop Avenanthramides and Beta Glucan active ingredients currently used in leading skincare brands worldwide. The Company’s common shares are listed on the TSX under the symbol “CSCI” and are listed and posted for trading on the OTCQB® Venture Market under the symbol “CSCIF”. For more information, please visit COSCIENS' website at .

Issuer Contact:

Peter H. Puccetti

Interim CEO and Chairman of the Board

Giuliano La Fratta

Chief Financial Officer





Investor Contact:



EN
07/04/2026

Underlying

CSCICOSCIENS BIOPHARMA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on COSCIENS BIOPHARMA INC

 PRESS RELEASE
Free
CSCI COSCIENS BIOPHA...

COSCIENS Comments on Unusual Market Activity

COSCIENS Comments on Unusual Market Activity TORONTO, ONTARIO, April 07, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is issuing this news release in response to unusual market activity. While the Company does not normally comment on market activity or market speculation, the Company confirms that it is not aware of any material undisclosed information relating to the Company that would account for the recent increase in trading activity in, and trading price of, the Company’s common shares. About COSCIENS Biopharma Inc. COSCIE...

April 7, 2026 1 EN
 PRESS RELEASE
Free
CSCI COSCIENS BIOPHA...

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Fina...

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on the development of natural, plant-based active ingredients, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2025. All amounts in this press release are in U.S. dollars. Corporate Update Following the reconstitution of the Company’s board of directors ...

March 25, 2026 1 EN
 PRESS RELEASE
Free
CSCI COSCIENS BIOPHA...

COSCIENS Provides Strategic Update

COSCIENS Provides Strategic Update TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”) today announced that the Company has made a strategic decision to cease funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH (the “German Subsidiaries”). As a result, the Company expects the German Subsidiaries to commence a structured insolvency process in the near future. The Company has historically pursued the development of its pharmaceutical therapeutic assets, including its main pharmaceutic...

March 5, 2026 1 EN
 PRESS RELEASE
Free
CSCI COSCIENS BIOPHA...

COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug I...

COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore TORONTO, ONTARIO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life sciences company focused on pharmaceutical therapies, diagnostic products, and natural ingredients solutions, today announced that its wholly-owned subsidiary, Aeterna Zentaris GmbH, has entered into an exclusive distribution agreement with Wuzhou Drug International Trading Limited (“Wuzho...

December 1, 2025 1 EN
 PRESS RELEASE
Free
CSCI COSCIENS BIOPHA...

COSCIENS Biopharma Inc. Announces Leadership Change

COSCIENS Biopharma Inc. Announces Leadership Change TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on natural ingredients and pharmaceutical solutions, announced today that Peter H. Puccetti, CFA, Chairman of the Company’s board of directors (the “Board”), has been appointed Interim Chief Executive Officer, effective immediately. Peter succeeds Anna Biehn, who has stepped down as Chief Executive Officer. “As the Company continues its efforts to reduce costs and streamlin...

November 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch